SCHEMBL19250367

SCHEMBL19250367

CCc1cc(Cl)cc(C(C)C)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.35
NOS3 P29474 2/20 0.34
NOS2 P35228 2/20 0.34
NOS1 P29475 1/20 0.34
PPARA Q07869 1/20 0.34
CRHR1 P34998 3/20 0.33
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
PDE4B Q07343 2/20 0.33
FABP4 P15090 1/20 0.32
KDM4E B2RXH2 1/20 0.32
DHFR P00374 2/20 0.31
CYP3A4 P08684 3/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
CYP2D6 P10635 2/20 0.31
SLC22A1 O15245 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17506423 0.80 NOS3 (0.43) ESR1NOS3NOS2CRHR1PDE4B
SCHEMBL17915875 0.80 NOS3 (0.43) ESR1NOS3NOS2NOS1GABRA1
SCHEMBL13064476 0.80 ESR1 (0.36) ESR1NOS3NOS2NOS1PPARA
SCHEMBL18068052 0.78 ESR1 (0.36) ESR1NOS3NOS2NOS1CRHR1
SCHEMBL13883322 0.76 ESR1 (0.35) ESR1NOS3NOS2NOS1CYP3A4
SCHEMBL19250366 0.76 ESR1 (0.35) ESR1NOS3NOS2NOS1CYP3A4
SCHEMBL22431506 0.76 ESR1 (0.35) ESR1NOS3NOS2NOS1CYP3A4
SCHEMBL4435970 0.75 NOS2 (0.61) NOS3NOS2NOS1DHFRCYP3A4
SCHEMBL25692611 0.75 NOS3 (0.36) NOS3NOS2NOS1GABRA1GABRB1
SCHEMBL15077328 0.74 NOS3 (0.39) NOS3NOS2NOS1GABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180037581-A1 HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING BRISTOL MYERS SQUIBB CO (US) 2018-02-08 US disclosed
US-9822112-B2 Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using BRISTOL-MEYERS SQUIBB COMPANY (US) 2017-11-21 US disclosed
US-20170233392-A1 HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING BRISTOL-MYERS SQUIBB COMPANY 2017-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233392-A1 HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING GABRA1, GABRA2, GABRA3 ESR1 432/4885NOS3 4441/4885NOS2 4371/4885
US-20180037581-A1 HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING GABRA1, GABRA2, GABRA3 ESR1 432/4885NOS3 4441/4885NOS2 4371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.